Per una migliore esperienza, mantieni il tuo browser aggiornato. Controlla qui le ultime versioni.

August 2022

Diadem Presents Data Showing Its Blood-Based Biomarker Test Can Both Diagnose and Predict Alzheimer’s Disease

Diadem, a company developing the first blood-based test for the early prediction of Alzheimer’s disease (AD) and based within OpenZone campus, this month reported that study data presented at the Alzheimer’s Association International Conference® 2022 (AAIC®) in San Diego USA confirms the strong diagnostic value of Diadem’s AlzoSure® Predict blood based biomarker test, as well as its excellent performance in identifying whether or not individuals will progress to AD years before the manifestation of clinical symptoms. The study data are included in a poster presentation1 that is being presented at AAIC® 2022 on August 3, 2022.
AlzoSure ®Predict uses a proprietary antibody (U-p53AZ) to measure blood levels of a conformational variant of the p53 protein that has been implicated in the pathogenesis of AD. Previous studies suggest that this p53 variant has utility as a diagnostic and as a predictive biomarker to identify individuals likely to progress to AD up to six years before symptoms appear.

The data Diadem is presenting at AAIC® 2022 confirms the diagnostic performance of AlzoSure® Predict for Alzheimer’s disease and highlights its potential as a prognostic test.

They are based on a longitudinal cohort of 479 individuals aged 60-85 years old in the Australian Imaging, Biomarkers, and Lifestyle (AIBL) study. In the present study, the assay achieved a sensitivity of 95% for AD, discriminating patients with AD from subjects with no memory complaints, with an AUC of 99.8% and a specificity of 99.6%, and from patients at the early symptomatic stage of AD with an AUC of 95.7% and a specificity of 91.8%.
 
Paul Kinnon
CEO at Diadem

 

We welcome the opportunity to present these study data at this important global meeting highlighting the performance of AlzoSure® Predict as both a diagnostic and prognostic test for Alzheimer’s disease. Based on these data and other studies, we are confident that AlzoSure® Predict has the potential to contribute to significant advances in the management of this devastating disease. We also are in the process of conducting additional studies to further confirm the prognostic power and utility of AlzoSure® Predict.

act

News

Scopri la sezione News per restare sempre aggiornato su ciò che riguarda gli zoner e sui temi pià rilevanti legati all'innovazione e alle Scienze della Vita.
tutte le news